Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 1/2 18Phase 1 7Phase 3 5Phase NA 3Phase EARLY_PHASE1 3Phase 4 2Phase 2/3 1

Status

Completed 129Recruiting 49Active not recruiting 32Unknown 30Terminated 20Not yet recruiting 10Withdrawn 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 2Ovarian Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Bevacizumab × Clear all
NCT04466917 2023-07-03

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Amgen

Phase 3 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Phase 3 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT03693573 2018-11-15

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Hoffmann-La Roche

Phase 3 Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT01338558 2016-11-02

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

Hoffmann-La Roche

Phase 3 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT00061178 2016-10-19

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Genentech, Inc.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡